|Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation|
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance (PVR) and subsequent reductions in cardiac output; these changes are further worsened by exercise. Inhaled nitric oxide (iNO) can decrease PVR and improve cardiac output in PAH patients.
In this study, the investigators looked at the effects of pulsed iNO on PVR and cardiac output in PAH patients with the CardioMEMS, an implantable hemodynamic monitoring device, both before and after exercise. Inhaled NO was delivered using Bellerophon’s proprietary INOpulse delivery system, that provides pulsed iNO in the ambulatory setting. The INOpulse delivery system is designed to be used chronically in outpatients and is currently in Phase 3 clinical trials for PAH.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contacts At Bellerophon: